Comparative Pharmacology
Head-to-head clinical analysis: GANCICLOVIR versus VITRAVENE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANCICLOVIR versus VITRAVENE PRESERVATIVE FREE.
GANCICLOVIR vs VITRAVENE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).
Antisense oligonucleotide that binds to mRNA of human cytomegalovirus (HCMV), inhibiting viral replication by blocking protein synthesis.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.
Intravitreal injection: 330 mcg (0.05 mL of 6.6 mg/mL solution) every 2 weeks for 2 doses, then every 4 weeks.
None Documented
None Documented
Clinical Note
moderateGanciclovir + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ganciclovir."
Clinical Note
moderateValganciclovir + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Valganciclovir."
Clinical Note
moderateGanciclovir + Mycophenolic acid
"The serum concentration of Mycophenolic acid can be increased when it is combined with Ganciclovir."
Clinical Note
moderateValganciclovir + Mycophenolic acid
Terminal half-life: 2.5-5.0 hours in normal renal function; prolonged to 10-30 hours in renal impairment; requires dose adjustment for CrCl <70 mL/min
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10 hours.
Renal excretion: >90% unchanged; biliary/fecal: minimal (<5%)
Primarily renal excretion. Approximately 40% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5%.
Category D/X
Category C
Antiviral
Antiviral
"The serum concentration of Mycophenolic acid can be increased when it is combined with Valganciclovir."